Hormonal
Muscle-specific overexpression of either IGF-1Ea or IGF-1Eb isoforms counteracts age-related sarcopenia by activating autophagy and PGC-1α-mediated mitochondrial biogenesis, thereby preserving muscle mass, force, and neuromuscular junction integrity without systemic side effects.
This research suggests that maintaining local muscle production of specific IGF-1 isoforms (Ea and Eb) is crucial for fighting age-related muscle loss. While this study used genetic modification in mice, it highlights that local muscle health mechanisms (autophagy and mitochondrial function) are key targets for preventing sarcopenia, rather than just relying on systemic hormone levels.
These data suggest that IGF-1 is a promising therapeutic agent in staving off advancing muscle weakness.
Why this rating
High-quality mechanistic evidence from transgenic mouse models with clear molecular and functional outcomes, though not human clinical trials.
Source
Effects of IGF‐1 isoforms on muscle growth and sarcopenia
Francesca Ascenzi et al. · Aging Cell · 2019
DOI 10.1111/acel.12954
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →